Upper respiratory tract infection

VTAMA® (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD

Retrieved on: 
Tuesday, June 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Cream, People, Efficiency, Acne, FDA, Patient, LTE, Vitiligo, LinkedIn, Journal, Adult, Nose, Research, American Academy, PGA, Itch, Common, Atopic dermatitis, Pain, Depression, Global Assessment of Functioning, Obesity, Risk, Therapy, Headache, Stinger, Psoriasis, Roivant Sciences, Folliculitis, Quality of life, Irritation, Rash, JD, Skin, Inflammatory bowel disease, Incidence, Hypertension, Swelling, Safety, Upper respiratory tract infection, Body surface area, Diabetes, Pharmaceutical industry, Cosmetics, MD, JAAD

VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.

Key Points: 
  • VTAMA Creams demonstrated combination of efficacy, remittive effect, durability and tolerability make it a strong addition to the psoriasis armamentarium.
  • Newly published final data in JAAD includes efficacy outcomes, quality of life, safety, and tolerability assessments observed over long-term use of VTAMA (tapinarof) Cream, 1%.
  • The PSOARING 3 LTE study forms part of Dermavants pivotal Phase 3 plaque psoriasis clinical program for VTAMA Cream.
  • On May 24, Dermavant announced that the FDA had approved VTAMA (tapinarof) Cream, 1% for the treatment of adult plaque psoriasis.

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Retrieved on: 
Thursday, June 23, 2022
Quality of life, Time, Association, Population, EASL, Poster, Hepatitis B, Liver disease, Institute of Liver and Biliary Sciences, SPARK, Augmented fifth, Health care, Company, Homeland Security Grant Program, Research, Growth, Ageing, European Association for the Study of the Liver, Upper respiratory tract infection, GLOBE, Recurrent genital herpes quality of life measure, Family, Diarrhea, Biomarker, Apache iBATIS, Nasdaq, Patient, Adult, SBA, Program, Pharmaceutical industry, Liver, Fever, PFIC, Sleep, Itch

Albireo also launched SPARK, a new grant-based program established to identify and drive improvements in the quality of care for rare liver diseases, beginning with PFIC in 2022.

Key Points: 
  • Albireo also launched SPARK, a new grant-based program established to identify and drive improvements in the quality of care for rare liver diseases, beginning with PFIC in 2022.
  • Key findings from the data include:
    Bylvay Responders Experience Improvements in Quality of Life Measures (poster #763).
  • Of 84 total patients in the pooled population, PedsQL data were available for 53 patients, and PEDsQL Family Impact (FI) data were available for 79 patients.
  • Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases.

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Biotechnology, Research, Surgery, Health, FDA, Clinical Trials, Blood, Wound, Inflammation, Pain, PLLA, Allergy, Toxin (comics), Vascular occlusion, Skin infection, Herbal, Muscle, History, Galderma, Hypertrophic scar, Tenderness, Human, Infection, Headache, Vitamin, Partnership, Bleeding, Myasthenia gravis, Red, Rash, Bajaj Consumer Care, Dermatology, Pimple, Sculptra, Catherine Disher, Infarction, Nausea, Bruise, Lip, Patient, ALS, Muscle weakness, Skin, Cyst, Skin discoloration, Use, Research, Nose, Medication, Amyotrophic lateral sclerosis, Upper respiratory tract infection, FDA, Risk, Face, Safety, Eyebrow, Death, Pharmaceutical industry, Cosmetics, Canning, Birth control, Dietary supplement, Medicine, Aesthetics, EU, Botulinum toxin, Ipsen

Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.

Key Points: 
  • Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.
  • We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine.
  • Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes.
  • Because we understand that the skin were in shapes our life stories, we are advancing dermatology for every skin story.

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lynx, ALT, Electrolyte, Constipation, Adult, Histology, Indigestion, Enzyme inhibitor, Antidiarrhoeal, Capecitabine, Nausea, HER3, CYP3A4, Fatigue, Abdominal pain, Food, Gastric acid, Puma Biotechnology, Arthralgia, Back pain, Dizziness, Upper respiratory tract infection, MBC, HER2, Appetite, FDA, Puma, Patient, Trastuzumab, Fetus, Kidney, Risk, Tablet, AST, Fulvestrant, Vomiting, Royal commission, Spasm, Diarrhea, Birth, Degenerative disease, Urinary tract infection, Stomatitis, European Commission, Transaminase, Rash, Fourth grade, Abdominal distension, Hepatotoxicity, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antacid, Neoplasm, Breast cancer classification, Safety, Pharmaceutical industry, Medical imaging, Vaccine

Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.

Key Points: 
  • Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
  • We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CR, Constipation, Follicular lymphoma, Company, Adult, Nausea, Abstract, Form 10-K, Fatigue, Abdominal pain, Form, Ageing, ASCO, Bristol Myers Squibb, Pain, Private Securities Litigation Reform Act, Upper respiratory tract infection, Appetite, Physician, EZH2, FDA, Patient, Review, COVID-19, SEC, Vomiting, Population, PET-CT, Lenalidomide, Lists of diseases, Celgene, Epithelioid sarcoma, Neoplasm, Mutation, Cancer, Safety, Medical imaging, Pharmaceutical industry

In addition to the SYMPHONY-1 presentation (Abstract # 7572 ), the Company has one additional tazemetostat study being presented during the ASCO Annual Meeting.

Key Points: 
  • In addition to the SYMPHONY-1 presentation (Abstract # 7572 ), the Company has one additional tazemetostat study being presented during the ASCO Annual Meeting.
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
  • The most common (20%) adverse reactions in patients with follicular lymphoma are fatigue, upper respiratory tract infection, musculoskeletal pain, nausea and abdominal pain.
  • Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines.

Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, People, Janus, Human, Adult, Pneumonia, HSCT, COVID, Nausea, Anemia, Abdominal pain, RA, Food, Psoriatic arthritis, Standard of care, Degenerative disease, Cancer, Bristol Myers Squibb, Hypermagnesemia, NIH, Upper respiratory tract infection, CD4, Lymphoma, Acute kidney injury, TNF, Hypoxia, BMY, Hematopoietic stem cell transplantation, JAK, National, Patient, Cough, Mortality, Risk, Host, NYSE, COVID-19, Lung cancer, MD, Hypertension, Diarrhea, Infection, Common, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Headache, Nosebleed, CMV, Safety, Methotrexate, Pharmaceutical industry, Vaccine, Fever, Vaccine, Abatacept

Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.

Key Points: 
  • Given the positive findings from the topline data, Bristol Myers Squibb plans to discuss these data and potential next steps with the U.S. Food and Drug Administration.
  • Hypersensitivity: There were 2 cases (
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
  • In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions

Retrieved on: 
Tuesday, May 31, 2022
Tendon rupture, Gout, Risk, Ezetimibe, Esperies, Moyamoya disease, Spasm, Pain, Pravastatin, Drug, FACC, Rupture, Disease, Abdominal pain, U.S. Securities and Exchange Commission, Atrial fibrillation, Lactation, Patient, Health, Kidney, COVID-19, FNLA, Mortality, FAHA, Uric acid, Shoulder, Pregnancy, Tablet, Fetus, Cholesterol, Forward-looking statement, Diet, Rotator cuff, Anemia, Achilles tendon, Back pain, Simvastatin, Security (finance), Bronchitis, Twitter, Growth, Bempedoic acid, Upper respiratory tract infection, Dietary supplement, Pharmaceutical industry, Hyperuricemia, Hyperuricemia, MD

ANN ARBOR, Mich., May 31, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced five abstracts have been accepted for presentation at the National Lipid Association Scientific Sessions (NLA 2022 Scientific Sessions) being held in-person in Scottsdale, Arizona.

Key Points: 
  • Limitations of Use: The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
  • Hyperuricemia may occur early in treatment and persist throughout treatment, and may lead to the development of gout, especially in patients with a history of gout.
  • Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
  • Esperion works hard to make our medicines easy to get, easy to take and easy to have.

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Retrieved on: 
Wednesday, May 18, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, ITT, Disease, Population, Ageing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Asthma, AES, Degenerative disease, AUC, Patient, COPD, NASDAQ, TSS, Viral load, Pharmacokinetics, Adult, Heart, Female, Medication, Immunity, RNA, Safety, Observation, Chronic obstructive pulmonary disease, Fast Track, RSVP, RSV, N, Upper respiratory tract infection, Institute of Liver and Biliary Sciences, Vaccine, Pharmaceutical industry

The effect on RSV RNA viral load is consistent with EDP-938s mechanism of action of inhibiting viral replication, said Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals.

Key Points: 
  • The effect on RSV RNA viral load is consistent with EDP-938s mechanism of action of inhibiting viral replication, said Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals.
  • RSVP was a Phase 2b, randomized, double-blind, multicenter, placebo-controlled study in ambulatory adults with or without comorbidities aged 18 to 75 years with confirmed RSV infection within 48 hours of symptom onset.
  • Patients were randomized 1:1 to receive once-daily 800 mg EDP-938 or placebo for 5 days and followed until Day 14.
  • Enantas research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV).

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, American Urological Association, Urination, Sex, Medicine, Urinary urgency, Urine, Sore throat, Overactive bladder, Vitamin, Neurogenic bladder dysfunction, Female, Nasal congestion, Urinary incontinence, Headache, Twitter, Science, Oakland University, Burden, Allergy, Nausea, Professor, Journal, Liver, Breast milk, Woman, Medical school, Beaumont, Vats, The Journal of Urology, Man, Urinary tract infection, Trial of the century, Diarrhea, NYSE, Department, Urinary retention, Catheter, Kopp, Digoxin, Doctor of Philosophy, I, Micturition syncope, Beaumont Hospital, Patient, OAB, Adult, FDA, Public health, LinkedIn, MD, Kidney, Upper respiratory tract infection, Population, Injection, Nocturia, Cystoscopy, Gesellschaft mit beschränkter Haftung, Safety, Pharmaceutical industry, Dietary supplement, Urology, Sexton

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Mutation, GAAP, Multiple myeloma, National Cancer Institute, Safety, Lymphoid leukemia, Ageing, SEC, Nausea, Pain, EZH2, Company, Private Securities Litigation Reform Act, Lists of diseases, NCCN, Patient, SETD2, FDA, SG, Workforce, Follicular lymphoma, Disease, B-cell lymphoma, Constipation, Epithelioid sarcoma, Vomiting, Methylation, Medicare, RNA, Fatigue, Upper respiratory tract infection, Neoplasm, Medicare Part D, Physician, Time, Bristol Myers Squibb, DNA, Sale, MM, RNA splicing, Journal of the National Comprehensive Cancer Network, Arm, COVID-19, Appetite, Nasdaq, Celgene, Form, DLBCL, Depreciation, Abdominal pain, Review, Webcast, Adult, Cancer, Form 10-K, Lymphoma, Society, ID, B cell, Pharmaceutical industry, Medical device, Video game, Lithium, Bank, Kerosene

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported first quarter 2022 financial results and provided a business update.

Key Points: 
  • Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported first quarter 2022 financial results and provided a business update.
  • Commercial demand increased 16% in the first quarter of 2022 versus the fourth quarter of 2021 levels while total demand (commercial demand and free goods supplied through the patient assistance program) in the first quarter of 2022 was similar to fourth quarter 2021 levels.
  • Epizyme, in collaboration with LYSA, anticipates presenting top-line results from the Phase 2 portion of the study in the second half of 2022.
  • Non-GAAP adjusted R&D expenses were $27.8 million for the first quarter of 2022, compared to $30.3 million for the first quarter of 2021.